Homepage Top Section2

If given approval, Nucala will become the first targeted anti-Interleukin-5 (IL-5) treatment in the country for adult and adolescent patients with SEA. A first-in-class monoclonal antibody to target

This funding round was primarily subscribed by current shareholders exercising their rights of first refusal. Leveraging this fund raise, Evergreen is launching a new business unit, called Evergreen

The deal was announced on 23 October 2022. Sumitovant has acquired all outstanding shares of Myovant it did not own through the all-cash deal. Following the completion of

The financing round, which brings the total funds raised by the firm to $143.5m, was led by EQT Life Sciences, investing from Droia Ventures, Sanofi Ventures and the

F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.

Under the agreement terms, Volastra receives an exclusive global license (ex-China) for the development and commercialisation of sovilnesib. Amgen will, in exchange, receive an upfront mix of cash

RAG-17 has been designed to act on and knockdown SOD1 expression in patients with pathogenic mutations that are known to cause ALS. The chemistry of the therapeutic is

Designed to modify SBMA through several mechanisms, AJ201 is currently in a Phase Ib/IIa study in the US to treat spinal and bulbar muscular atrophy (SBMA), which is

Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to